Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Storey

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Soft Matter|July 23, 2016
Understanding the twist-bend nematic phase: the characterisation of 1-(4-cyanobiphenyl-4'-yloxy)-6-(4-cyanobiphenyl-4'-yl)hexane (CB6OCB) and comparison with CB7CBDaniel A Paterson, Min Gao, Young-Ki Kim, et al.
Lancet (London, England)|November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trialSerge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaHelen Shiells, Bjoern O Schelter, Peter Bentham, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2017
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical TrialGordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, et al.
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Soft Matter|July 23, 2016
Understanding the twist-bend nematic phase: the characterisation of 1-(4-cyanobiphenyl-4'-yloxy)-6-(4-cyanobiphenyl-4'-yl)hexane (CB6OCB) and comparison with CB7CBDaniel A Paterson, Min Gao, Young-Ki Kim, et al.
Lancet (London, England)|November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trialSerge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaHelen Shiells, Bjoern O Schelter, Peter Bentham, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2017
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical TrialGordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, et al.
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
Pageof 8